- Home
- IPHA vs ABOS Comparison
IPHA vs ABOS Comparison
Compare IPHA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- ABOS
- Stock Information
- Founded
- IPHA 1999
- ABOS 1996
- Country
- IPHA France
- ABOS United States
- Employees
- IPHA N/A
- ABOS N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- ABOS Health Care
- Exchange
- IPHA Nasdaq
- ABOS Nasdaq
- Market Cap
- IPHA 191.0M
- ABOS 166.4M
- IPO Year
- IPHA 2019
- ABOS 2021
- Fundamental
- Price
- IPHA $2.17
- ABOS $2.55
- Analyst Decision
- IPHA Strong Buy
- ABOS Strong Buy
- Analyst Count
- IPHA 1
- ABOS 4
- Target Price
- IPHA $11.50
- ABOS $9.00
- AVG Volume (30 Days)
- IPHA 6.3K
- ABOS 171.4K
- Earning Date
- IPHA 09-12-2024
- ABOS 08-13-2024
- Dividend Yield
- IPHA N/A
- ABOS N/A
- EPS Growth
- IPHA N/A
- ABOS N/A
- EPS
- IPHA N/A
- ABOS N/A
- Revenue
- IPHA $36,202,722.00
- ABOS N/A
- Revenue This Year
- IPHA N/A
- ABOS N/A
- Revenue Next Year
- IPHA $105.84
- ABOS N/A
- P/E Ratio
- IPHA N/A
- ABOS N/A
- Revenue Growth
- IPHA N/A
- ABOS N/A
- 52 Week Low
- IPHA $1.81
- ABOS $1.81
- 52 Week High
- IPHA $3.15
- ABOS $5.65
- Technical
- Relative Strength Index (RSI)
- IPHA 49.44
- ABOS 48.90
- Support Level
- IPHA $2.22
- ABOS $2.15
- Resistance Level
- IPHA $2.41
- ABOS $2.55
- Average True Range (ATR)
- IPHA 0.12
- ABOS 0.16
- MACD
- IPHA -0.00
- ABOS 0.01
- Stochastic Oscillator
- IPHA 47.06
- ABOS 56.64
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.